How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

645 results for

Subclinical Hyperthyroidism

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Hemostasis in Overt and Subclinical Hyperthyroidism (PubMed)

Hemostasis in Overt and Subclinical Hyperthyroidism There are contradictory results on the effect of hyperthyroidism on hemostasis. Inadequate population-based studies limited their clinical implications, mainly on the risk of venous thromboembolism (VTE). The present review focuses on hemostatic changes in overt and subclinical hyperthyroidism.A systematic literature search was conducted employing MEDLINE database. The following words were used for the search: Hyperthyroidism; thyrotoxicosis (...) ; Graves disease; goiter, nodular; hemostasis; blood coagulation factors; blood coagulation disorders; venous thromboembolism; bleeding; fibrinolysis. The articles that were related to hyperthyroidism and hemostasis are used in this manuscript.Hyperthyroidism, either overt or subclinical, renders a hypercoagulable state, although there are several studies with contradictory findings in the literature. Hypercoagulability may be caused by an increase in the level of various coagulation factors

Full Text available with Trip Pro

2017 International journal of endocrinology and metabolism

2. Screening and treatment of subclinical hypothyroidism or hyperthyroidism

Screening and treatment of subclinical hypothyroidism or hyperthyroidism Screening and treatment of subclinical hypothyroidism or hyperthyroidism Screening and treatment of subclinical hypothyroidism or hyperthyroidism Rugge B, Balshem H, Sehgal R, Relevo R, Gorman P, Helfand M Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Rugge B (...) , Balshem H, Sehgal R, Relevo R, Gorman P, Helfand M. Screening and treatment of subclinical hypothyroidism or hyperthyroidism. Rockville: Agency for Healthcare Research and Quality (AHRQ). Comparative Effectiveness Review No. 24. 2011 Authors' conclusions Currently there are no studies that evaluate the benefits and harms of screening for subclinical thyroid dysfunction in the primary care setting. Studies of treatment tend to be small and of short duration, and they have failed to demonstrate

2011 Health Technology Assessment (HTA) Database.

3. Screening and Treatment of Subclinical Hypothyroidism or Hyperthyroidism

Screening and Treatment of Subclinical Hypothyroidism or Hyperthyroidism Screening and Treatment of Subclinical Hypothyroidism or Hyperthyroidism | Effective Health Care Program Search Effective Health Care website Submit search Toggle navigation Select site to search Search Effective Health Care website Submit search Screening and Treatment of Subclinical Hypothyroidism or Hyperthyroidism Mar. 10, 2010 Nov. 14, 2011 Systematic Review May. 2, 2012 Disposition of Comments Report Screening (...) and Treatment of Subclinical Hypothyroidism or Hyperthyroidism Systematic Review Archived November 14, 2011 1.5 MB Related Files Archived : This report is greater than 3 years old. Findings may be used for research purposes, but should not be considered current. People using assistive technology may not be able to fully access information in these files. For additional assistance, please . Structured Abstract Objectives This report focused on four questions: Does screening for subclinical thyroid

2011 Effective Health Care Program (AHRQ)

4. The natural history of subclinical hyperthyroidism in Graves' disease - the rule of thirds. (PubMed)

The natural history of subclinical hyperthyroidism in Graves' disease - the rule of thirds. There is little information regarding the natural history of subclinical hyperthyroidism (SH) due to Graves' disease (GD).A prospective analysis was conducted of patients with SH due to GD between 2007 and 2013 with at least 12 months of follow-up. SH was diagnosed if serum thyrotropin (TSH) was below the laboratory reference range (0.4-4.0 mIU/L) and when thyroid hormones were normal. GD was confirmed (...) by either a raised TSH receptor antibody (TRAb) level or uniform uptake on Technetium scan.Forty-four patients (89% female, 16% current smokers, and 5% with active Graves' orbitopathy) were diagnosed with SH due to GD. Over the follow-up period (median 32 months), approximately one third (34%) of the cohort progressed to overt hyperthyroidism, one third (34%) normalized their thyroid function, slightly less than one third (30%) remained in the SH state, while one person became hypothyroid. Multivariate

2016 Thyroid

5. Subclinical Hyperthyroidism

Subclinical Hyperthyroidism Subclinical Hyperthyroidism Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Subclinical Hyperthyroidism (...) Subclinical Hyperthyroidism Aka: Subclinical Hyperthyroidism From Related Chapters II. Definition Euthyroid patient with TSH suppression Low but detectable TSH: 0.1 to 0.4 mIU/L Suppressed TSH: <0.1 mIU/L (greatest association with adverse effects, esp. >65 years old) III. Epidemiology in U.S. (study included patients over age 12 years old) TSH <0.4 mIU/L: 3.2% TSH <0.1 mIU/L: 0.7% More common in older agults Prevalance in age over 70 years approaches 15% in deficient regions IV. Causes Over-treatment

2018 FP Notebook

6. Evaluation of endothelial function in exogenous subclinical hyperthyroidism and the effect of treatment (PubMed)

Evaluation of endothelial function in exogenous subclinical hyperthyroidism and the effect of treatment Subclinical hyperthyroidism (SHy) is a widespread condition in which cardiovascular manifestations are frequently occur, but there is still a debate about the vascular responsiveness in it. Measuring flow-mediated dilation (FMD) and intimae-media thickness (IMT) are used to evaluate endothelial function in these patients.Twenty-five patients with a diagnosis of exogenous SHy and 25 full (...) , respectively. The mean of FMD in healthy people was dramatically higher than the subclinical hyperthyroid patients (P < 0.001) but no statistically significant difference was found for IMT (P = 0.459). After intervention in the case group, FMD was meaningfully increased (P < 0.001) but IMT of common carotid artery was not considerably changed (P = 0.491).This study demonstrated that FMD decreased in exogenous subclinical hyperthyroid patients which could be partially restored by treatment. These findings

Full Text available with Trip Pro

2016 Advanced biomedical research

7. Hypokalaemic Periodic Paralysis in a Patient with Subclinical Hyperthyroidism: A Rare Case (PubMed)

Hypokalaemic Periodic Paralysis in a Patient with Subclinical Hyperthyroidism: A Rare Case Thyrotoxic Periodic Paralysis (TPP) is an uncommon disorder. Though many cases of hypokalaemic periodic paralysis are reported in overt hyperthyroidism, hypokalaemic paralysis in subclinical hyperthyroidism is very rare. Subclinical hyperthyroidism is characterised by circulating TSH levels below reference range and normal thyroid hormone levels. We describe a case of 32-year-old Asian male who presented (...) to the emergency department with acute onset weakness and hypokalaemia with no previous history of thyroid disorder or any signs and symptoms suggestive of hyperthyroidism. He was subsequently diagnosed with Graves' disease with subclinical hyperthyroidism.

Full Text available with Trip Pro

2016 Journal of clinical and diagnostic research : JCDR

8. Electrocardiographic and scintigraphic evaluation of patients with subclinical hyperthyroidism during workout (PubMed)

Electrocardiographic and scintigraphic evaluation of patients with subclinical hyperthyroidism during workout Subclinical hyperthyroidism (sHT) was found to be associated with elevated heart rate, blood pressure and increased risk of extrasystoles. However, the full clinical relevance of morphological and functional implications of sHT on the cardiovascular system is still a matter of debate. The aim of the study was to prospectively assess the influence of endogenous sHT on exercise capacity

Full Text available with Trip Pro

2016 Endocrine

9. Echocardiographic evolution of pulmonary hypertension in female patients with hyperthyroidism (PubMed)

groups: groups A (overt hyperthyroidism), B (recurrent disease), and C (subclinical forms). We performed echocardiography to determine echocardiographically estimated systolic pulmonary arterial pressure (eePAP), CO, and PVR before and at 3, 6, and 12 months after treatment with thyroid suppression therapy and beta-blockers.In our study group we documented PH of various severities in 73 patients (51.4%). Increased CO, induced mostly by hyperthyroidismspecific tachycardia, was frequently detected (...) Echocardiographic evolution of pulmonary hypertension in female patients with hyperthyroidism The objective of this study was to highlight the impact of increased cardiac output (CO) and/or pulmonary vascular resistance (PVR) on the occurrence and evolution of pulmonary hypertension (PH) in hyperthyroidism and to follow their evolution in patients under therapy.Our study group consisted of 142 women with hyperthyroidism of different severities and etiologies. We divided our patients into three

Full Text available with Trip Pro

2018 Anatolian journal of cardiology

10. A patient-specific treatment model for Graves’ hyperthyroidism (PubMed)

predictions with data from four patients.When there is no MMI treatment, there is a unique asymptotically stable hyperthyroid state. After the initiation of MMI treatment, the hyperthyroid state moves towards subclinical hyperthyroidism and then euthyroidism.We can use the model to describe or test and predict patient treatment schedules. More specifically, we can fit the model to individual patients' data including loading and maintenance doses and describe the mechanism, hyperthyroidism→euthyroidism (...) A patient-specific treatment model for Graves’ hyperthyroidism Graves' is disease an autoimmune disorder of the thyroid gland caused by circulating anti-thyroid receptor antibodies (TRAb) in the serum. TRAb mimics the action of thyroid stimulating hormone (TSH) and stimulates the thyroid hormone receptor (TSHR), which results in hyperthyroidism (overactive thyroid gland) and goiter. Methimazole (MMI) is used for hyperthyroidism treatment for patients with Graves' disease.We have developed

Full Text available with Trip Pro

2018 Theoretical biology & medical modelling

11. Validity and Reliability of the Korean Version of the Hyperthyroidism Symptom Scale (PubMed)

Validity and Reliability of the Korean Version of the Hyperthyroidism Symptom Scale Thyrotoxicosis is a common disease resulting from an excess of thyroid hormones, which affects many organ systems. The clinical symptoms and signs are relatively nonspecific and can vary depending on age, sex, comorbidities, and the duration and cause of the disease. Several symptom rating scales have been developed in an attempt to assess these symptoms objectively and have been applied to diagnosis (...) or to evaluation of the response to treatment. The aim of this study was to assess the reliability and validity of the Korean version of the hyperthyroidism symptom scale (K-HSS).Twenty-eight thyrotoxic patients and 10 healthy subjects completed the K-HSS at baseline and after follow-up at Seoul National University Bundang Hospital. The correlation between K-HSS scores and thyroid function was analyzed. K-HSS scores were compared between baseline and follow-up in patient and control groups. Cronbach's α

Full Text available with Trip Pro

2018 Endocrinology and Metabolism

12. Hyperthyroidism and papillary thyroid carcinoma in thyrotropin receptor D633H mutant mice. (PubMed)

this model, both subclinical and overt hyperthyroidism was observed, depending on the age, sex, and genotype. Homozygous mice presented hyperthyroidism at two months of age, while heterozygous animals showed only suppressed thyrotropin. Interestingly, at six months of age, thyroid hormone concentrations in all mutant mice were analogous to wild-type mice, and they showed colloid goiter with flattened thyrocytes. Strikingly, at one year of age, nearly all homozygous mice presented large papillary thyroid (...) Hyperthyroidism and papillary thyroid carcinoma in thyrotropin receptor D633H mutant mice. Constitutively active thyrotropin receptor (TSHR) mutations are the most common etiology of non-autoimmune hyperthyroidism (NAH). Thus far, the functionality of these mutations has been tested in vitro, but the in vivo models are lacking.To understand the pathophysiology of NAH, the patient-derived constitutively active TSHR D633H mutation was introduced into the murine Tshr by homologous recombination.In

2018 Thyroid

13. Subclinical thyroid dysfunction is associated with adverse prognosis in heart failure patients with reduced ejection fraction. (PubMed)

Subclinical thyroid dysfunction is associated with adverse prognosis in heart failure patients with reduced ejection fraction. Subclinical thyroid dysfunction whose typical patterns include subclinical hypothyroidism and subclinical hyperthyroidism, has been indicated to be associated with an increased risk of heart failure (HF). However, the relationship between subclinical thyroid dysfunction and the clinical outcomes of HF patients is uncertain. This meta-analysis was conducted to assess (...) ). Subclinical hyperthyroid can increase the risk of all-cause mortality without heterogeneity (HR 1.31, 95% CI 1.10-1.55, I2 = 25.5%, P = 0.225) but have no influence on the risk of cardiac death and/or hospitalization (HR 1.03, 95% CI 0.87-1.23, I2 = 0.0%, P = 0.958). These significant adverse associations were also retained in subgroup analysis. Sensitivity analysis demonstrated the stability of the results of our meta-analysis.Both subclinical hypothyroidism and subclinical hyperthyroidism are associated

Full Text available with Trip Pro

2019 BMC Cardiovascular Disorders

14. Hyperthyroidism

of the thyroid gland, such as in Graves' disease. Secondary hyperthyroidism occurs when thyrotoxicosis is caused by abnormal stimulation of a normal thyroid gland, such as by a TSH-secreting pituitary tumour. Subclinical hyperthyroidism is diagnosed when TSH is suppressed but FT4 and FT3 concentrations are within the normal reference range. The complications of hyperthyroidism include: Graves' orbitopathy. Thyroid storm (thyrotoxic crisis). Atrial fibrillation. Heart failure. Reduced bone mineral density (...) subclinical hyperthyroidism. Specialist treatment options such as antithyroid drugs, radioiodine treatment, or thyroid surgery. All women with overt or subclinical hyperthyroidism who are planning a pregnancy should be referred to an endocrinologist for pre-pregnancy counselling, and should be advised to seek medical advice immediately if pregnancy is suspected. All women with overt or subclinical hyperthyroidism who are pregnant should be referred urgently to a joint obstetric and endocrinology clinic

2016 NICE Clinical Knowledge Summaries

15. Excess mortality in treated and untreated hyperthyroidism is related to cumulative periods of low serum TSH. (PubMed)

Excess mortality in treated and untreated hyperthyroidism is related to cumulative periods of low serum TSH. Cumulative time-dependent excess mortality in hyperthyroid patients has been suggested. However, the effect of antithyroid treatment on mortality, especially in subclinical hyperthyroidism, remains unclarified. We investigated the association between hyperthyroidism and mortality in both treated and untreated hyperthyroid individuals.Register-based cohort study of 235,547 individuals who (...) had at least one serum thyroid-stimulating hormone (TSH) measurement in the period 1995 to 2011 (7.3 years median follow-up). Hyperthyroidism was defined as at least two measurements of low serum TSH. Mortality rates for treated and untreated hyperthyroid subjects compared with euthyroid controls were calculated using multivariate Cox regression analyses, controlling for age, sex, and comorbidities. Cumulative periods of decreased serum TSH were analyzed as a time-dependent covariate.Hazard ratio

Full Text available with Trip Pro

2017 Journal of Clinical Endocrinology and Metabolism

16. Efficacy of Low‐dose (2 millicurie) versus Standard‐dose (4 millicurie) Radioiodine Treatment for Cats with Mild‐to‐Moderate Hyperthyroidism (PubMed)

), subclinical hypothyroidism (normal T4 , high TSH), and azotemia.There was no significant difference in prevalence of cats with persistent hyperthyroidism between standard- and low-dose treatment groups at 3 (0% versus 5.3%; P = .34) and 6 (0% versus 3.3%; P = .51) months. Overt (18% versus 1%; P = .0005) or subclinical (46% versus 21%; P = .004) hypothyroidism was more common in cats at 6 months after standard-dose 131 I. No difference in incidence of azotemia existed between groups, but cats treated (...) Efficacy of Low‐dose (2 millicurie) versus Standard‐dose (4 millicurie) Radioiodine Treatment for Cats with Mild‐to‐Moderate Hyperthyroidism Radioiodine (131 I) is effective treatment for hyperthyroidism in cats, but optimal dose to restore euthyroidism without inducing hypothyroidism is unclear. Treatment-induced hypothyroidism can lead to azotemia and reduced duration of survival.To compare efficacy and short-term outcomes of low-dose 131 I versus higher, standard-dose 131 I

Full Text available with Trip Pro

2017 Journal of Veterinary Internal Medicine

17. Novel germline mutation (Leu512Met) in the thyrotropin receptor gene (TSHR) leading to sporadic non-autoimmune hyperthyroidism (PubMed)

Novel germline mutation (Leu512Met) in the thyrotropin receptor gene (TSHR) leading to sporadic non-autoimmune hyperthyroidism Primary nonautoimmune hyperthyroidism is a rare cause of neonatal hyperthyroidism. This results from an activating mutation in the thyrotropin-receptor (TSHR). It can be inherited in an autosomal dominant manner or occur sporadically as a de novo mutation. Affected individuals display a wide phenotype from severe neonatal to mild subclinical hyperthyroidism. We describe (...) hyperthyroidism.

Full Text available with Trip Pro

2017 Journal of pediatric endocrinology & metabolism : JPEM

18. Atrial fibrillation and hyperthyroidism: A literature review (PubMed)

: 1. The relationship of atrial fibrillation to hyperthyroidism 2. Atrial fibrillation as a predictor of hyperthyroidism 3. The pathophysiology of thyrotoxic atrial fibrillation 4. Subclinical hyperthyroidism and the relationship with atrial fibrillation 5. Cardioversion and Catheter ablation of hyperthyroid patients with atrial fibrillation 6. Thrombotic risk of hyperthyroid patients with atrial fibrillation 7. Management of Thyrotoxic Atrial fibrillation 8. Pharmacological rhythm control (...) Atrial fibrillation and hyperthyroidism: A literature review Atrial fibrillation is the most common arrhythmia worldwide with increasing frequency noted with age. Hyperthyroidism is a well-known cause of atrial fibrillation with a 16%-60% prevalence of atrial fibrillation in patients with known hyperthyroidism Ross et al. (2016). While hyperthyroidism as a causative factor of atrial fibrillation is well established, this literature review aims to answer several questions on this topic including

Full Text available with Trip Pro

2017 Indian heart journal

19. Subclinical hypothyroidism is an independent predictor of adverse cardiovascular outcomes in patients with acute decompensated heart failure (PubMed)

was to identify the prevalence and prognostic impact of low-T3 syndrome and subclinical thyroid dysfunction in patients with acute decompensated heart failure (ADHF).We examined 274 ADHF patients who were not receiving thyroid medication or amiodarone on admission (70 ± 15 years, 156 male), who underwent thyroid function tests. Euthyroidism was defined as TSH of 0.45 to 4.49 mIU/L; subclinical hypothyroidism as TSH of 4.5 to 19.9 mIU/L; and subclinical hyperthyroidism as TSH < 0.45 mIU/L, with normal free T4 (...) level for the last two. Additionally, low-T3 syndrome was defined as free T3 < 4.0 pmol/L among euthyroidism subjects. On admission, 188 patients (69%) showed euthyroidism, 58 (21%) subclinical hypothyroidism, 5 (2%) subclinical hyperthyroidism, and 95 (35%) low-T3 syndrome. Cox proportional hazards models revealed that higher TSH, but not free T3 and free T4, was independently associated with composite cardiovascular events, including cardiac death and re-hospitalization for heart failure. Indeed

Full Text available with Trip Pro

2016 ESC heart failure

20. Prevalence of subclinical hypothyroidism in adults visiting primary health-care setting in Riyadh (PubMed)

participants in the study gave blood samples. Subclinical hyperthyroidism was identified in 2.1% (p = .001) and subclinical hypothyroidism in 10.3% (p = .001) of the PHC visitors. TSH levels were found to be significantly higher (p = .047) in elderly population of ≥60 years and those with family history of thyroid disease. Non-significant upward trends were noted in TSH levels with hyperlipidemia and increasing blood pressure. No overt hyperthyroidism or hypothyroidism was found in our study sample (...) Prevalence of subclinical hypothyroidism in adults visiting primary health-care setting in Riyadh Background and objectives: Subclinical hypothyroidism is an asymptomatic condition with normal thyroxin and raised thyroid stimulating hormone (TSH) level. The objective of the study was to determine the prevalence of subclinical hypothyroidism in primary health care (PHC) settings in Riyadh and explore the relationship of TSH level with age, gender, family history, body mass index, and co-morbid

Full Text available with Trip Pro

2018 Journal of community hospital internal medicine perspectives

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>